Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2025-09-12 Interim / Quarterly Rep…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Relazione finanziaria semestrale 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RESOCONTO INTERMEDIO DI GESTIONE RELAZIONE FINANZIARIA SEMESTRALE' (Interim Management Report - Half-Yearly Financial Report) for the period ending June 30, 2025. It contains comprehensive financial statements, including the consolidated balance sheet, income statement, and explanatory notes, as well as management's discussion and analysis of the group's performance. It is a full interim report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-12 Italian
CS_Disponibilità Relazione Semestrale 2025 || Availability Half Year financial report 2025
Report Publication Announcement Classification · 1% confidence The document is a short press release (4 pages, mostly images and contact info) announcing the availability of the 'First-Half Financial Report as of June 30, 2025'. It does not contain the actual financial statements, but rather informs the public where they can be accessed (company website, registered office, and eMarket Storage). Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-09-12 Italian
PHN: The Board of Directors approved the results as of 30 June 2025
Earnings Release Classification · 1% confidence The document is a detailed financial report for the first half of 2025 (ending 30 June 2025) for PharmaNutra S.p.A. It includes consolidated results, analysis of sales revenues, product line performance, operating costs, and a management outlook. While it begins with a press release format, the content provides a comprehensive breakdown of the interim financial performance, which fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-08 English
PHN: il Consiglio di Amministrazione ha approvato i risultati al 30 giugno 2025
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of the fiscal year 2025 (ending June 30, 2025) for PharmaNutra S.p.A. It contains detailed financial statements, including income statements, balance sheet data, and management analysis of results, revenue by product line, and significant events. It is not merely an announcement or a short summary, but a substantive report detailing financial performance. Therefore, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-08 Italian
PR PHARMANUTRA SPA - Sidevit B12 sales
Regulatory Filings Classification · 1% confidence The document is a press release issued by PharmaNutra S.p.A. regarding the sales performance of a specific product, 'Sidevit B12', in the first half of 2025. It provides market data, rankings, and management commentary on the product's success. It does not constitute a full quarterly or annual financial report, nor is it a regulatory filing for a specific event like a board change or dividend declaration. As it is a corporate announcement regarding business performance and product success, it falls under the category of general regulatory announcements/press releases.
2025-08-04 English
CS PHARMANUTRA SPA - Vendite Sidevit B12
Earnings Release Classification · 1% confidence The document is a press release issued by Pharmanutra S.p.A. regarding the sales performance of a specific product, 'Sidevit B12'. It contains regulatory headers typical of Italian stock exchange filings (Euronext Star Milan) and is categorized as a corporate communication. Since it is a general regulatory announcement regarding business performance that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). H1 2025
2025-08-04 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.